Sanger sequencing is used to study a small subset of genes linked to a defined phenotype, confirm next-generation sequencing (NGS) variants, detect minor allele fractions down to 5%, or read contiguous sequences up to 1,000 bases. 

Fragment analysis is a powerful technique with simple, straightforward workflows and used in a wide-range of applications, such as detection of mutations, genotyping, identification of short tandem repeats, and gene expression profiling.

Applied Biosystems genetic analysis systems are a trusted standard for Sanger sequencing and fragment analysis by capillary electrophoresis—proven through decades of results, including the first sequencing of the human genome and the discovery of genes implicated in diseases like cystic fibrosis. 

Solutions for Sanger sequencing and fragment analysis
Sanger sequencing and fragment analysis are foundational applications in a range of clinical environments from clinical research to clinical reference laboratories.
Sequence confirmation is critical during mRNA therapeutic and vaccine manufacturing. Trust Sanger sequencing to get it right.

Sanger sequencing is the gold standard for sequencing technology since it provides a high degree of accuracy, long-read capabilities, and the flexibility to support a diverse range of applications in many research areas

Learn more about the applications fragment analysis enables, from microsatellite marker analysis in cell line authentication (CLA) to multiplex ligation-dependent probe amplification (MLPA) assay in inherited disease research

Learn more about each step of the recommended
workflow, from DNA and RNA isolation and PCR amplification to capillary electrophoresis and
data analysis

Learn how fluorescently labeled DNA fragments are separated using capillary electrophoresis (CE) and sized by comparison to a size standard

1650013681892.jpg

Webinar: Multivariate analysis using targeted sequence interrogation

Learn how incorporating fragment analysis could better manage postoperative pain control.

View on Demand

Power_point_title_slide-h

Webinar: Multiplexed identification of viruses & bacteria

Case studies highlighting the untapped potential of fragment analysis

View on demand

Planning to commercialize or resell a product or assay?

If you have plans to commercialize, you’re likely on a strict timeline. Therefore, you'll want to work with our Genetic Sciences OEM and commercial supply team to ensure you get the:

  • Right technology to support your go-to-market plan
  • Proper supply agreements, commercial-use or licensing rights
  • Commercial-use product SKUs for regulatory submissions
  • Custom kitting or bulk order packaging... and more

Our Business Development Managers are your dedicated partners to help you avoid unnecessary delays due to not having the right information at the start of your commercialization journey.

Learn more about OEM & commercial supply ➔

Scientist Spotlights

Learn how scientists are finding answers to complex and challenging questions through perseverance and technology.

Athena Starlard-Davenport, PhD

University of Tennessee Health Science Center (UTHSC)

Breast Cancer Disparity Among African-American Women: Insights Powered by Sanger Sequencing

Gregory O’Corry-Crowe, PhD

Harbor Branch Oceanographic Institute, Florida Atlantic University

Life on the Edge: Using Genetic Analysis to Track Beluga Whales in a Changing Arctic

Build your knowledge

Build your knowledge

Get bite-sized answers to your everyday Sanger sequencing and fragment analysis questions

Learn about the history of sequencing and how to pick the right platform for your research needs

For Research Use Only. Not for use in diagnostic procedures.